— Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
— Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
— Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
— BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
— New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
— Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
— Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
— High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
— Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
Citalopram may prevent depression in patients with head and neck cancer
Taking the antidepressant citalopram before beginning treatment for head and neck cancer may help prevent depression during therapy, according to results of a pilot study published in the May issue of Archives of Otolaryngology - Head and Neck Surgery, one of the JAMA/Archives journals.
'Treatment for head and neck cancer can be arduous and debilitating,' the authors write as background information in the article. 'Psychiatric morbidity in these patients is frequent and underdiagnosed. Major depressive disorder has been reported in up to 40 percent of patients with head and neck cancer, typically within the first three months of diagnosis.'
William M. Lydiatt, M.D., of the University of Nebraska Medical Centre and Nebraska Methodist Hospital, Omaha, and colleagues conducted a randomised clinical trial involving patients with head and neck cancer. Before beginning treatment, 15 participants were randomly assigned to receive 40 milligrams of the antidepressant citalopram daily and 13 were randomly assigned to take placebo. The patients took the medications for 12 weeks, during which time they underwent cancer treatment and were screened for depression every four weeks. Twenty-two patients were assessed at week 12, and 23 patients completed a final study visit four weeks after stopping the medication.
'The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were five of 10 (50 percent) taking placebo and two of 12 (17 percent) taking citalopram,' the authors write. 'No patients in the citalopram group became suicidal, compared with two in the placebo group.' Quality of life, as measured by a self-administered questionnaire, deteriorated in both groups during treatment but less so in the group taking citalopram.
'The data from this pilot trial suggest that prevention of major depressive disorder in patients undergoing treatment for head and neck cancer may be an attainable goal. The data show trends toward major depressive disorder prevention in this small sample. All measures of psychiatric well-being favoured the group taking citalopram,' the authors conclude. 'This study suggests a tangible means to improve outcome in patients with head and neck cancer and supports additional research toward this aim.'
Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.
Scientists identify compound that could prevent HIV transmission
Breakthrough makes lab-produced stem cells safer for humans
Magnetic device studied as treatment for heartburn and acid reflux
Injections of licorice ingredient show promise as treatment for cocaine addiction